BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Novartis AG (NVS) Seeks Approval for New Smoker's Cough Drug


9/27/2011 8:07:23 AM

Swiss drugmaker Novartis said it has applied to start selling its experimental drug to treat smoker's cough -- which afflicts 80 million people worldwide -- after tests showed that it helped patients breathe more easily. Novartis has carried out late-stage trials for the drug, known as NVA237, because it wants to tap into the lucrative market for respiratory drugs at a time when it is facing increasing competition for its top-selling products from generic rivals. Analysts say Novartis could earn billions of dollars if its treatments for chronic obstructive pulmonary disease (COPD), commonly known as smoker's cough, win regulatory approval. NVA237 alone could potentially add $500 million in annual sales.

Read at News Release
Read at Reuters
Read at RTT News
Read at Wall Street Journal

   
Addiction

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES